SPDEF, a target gene of ESR1, overexpressed in breast and other solid tumors, was shown to be associated with worse outcomes in patients with ER+ breast cancers and to be critical for the survival of ER+ breast cancer cells in vitro [49]. This evidence concerns the gene ESR1 and breast carcinoma.